|
NPPA revises ceiling prices of 21 scheduled drugs and retail prices of 21 formulations
|
|
Our Bureau, Mumbai
September 21 , 2016
|
|
|
The National Pharmaceutical Pricing Authority (NPPA) has fixed/revised
ceiling prices of 21 scheduled formulations of Schedule-I under Drugs
(Prices Control) Amendment Order, 2016 and retail price of 21
formulations under DPCO, 2013 through a Notification/order dated
15.9.2016.
Name of the scheduled formulations are paracetamol
oral liquid, cefadroxil tablet, cefazolin powder for injection,
kanamycin powder for injection, cyclosporin capsule, primaquine tablet,
methotrexate tablet, levodopa + carbidopa tablet, hydrochlorothiazide
tablet, carbamazepine tablet, sodium valproate injection, enoxaparin
injection, cholecalciferol (vitamin D3) capsule, cholecalciferol
(vitamin D3) tablet and levetiracetam oral liquid.
Retail price
of scheduled formulations are formoterol fumarate + budesonide respules
(budamate neb 0.5mg), formoterol fumarate + budesonide respules
(budamate neb 1mg), atorvastatin + choline fenofibrate DR capsule,
diclofenac capsule (IER-75), metoprolol + olmesartan tablet (Olkem Beta
25) olmesartan +metoprolol tablet (Olkem Beta 50), rosuvastatin +
aspirin capsule (Zyrova ASP 150), tolperisone HCl + diclofenac sodium
tablet (Tolkem-D), glimepiride + metformin HCl tablet (Glucoryl M3
Forte), glimepiride + metformin tablet (Glucoryl M3), amoxycillin +
clavulanic acid tablet (Pencalv 1000), cefixime trihydrate+ ofloxacin
tablet (Jetex OF), teneligliptin+ metformin HCl ER tablet (Megagliptin
MF Forte), teneligliptin + metformin HCl SR tablet (Dynaglipt M Forte),
povidone iodine+ ornidazole ointment (Lupidine - OZ), glimepiride tablet
(Glucoryl 3mg), clotrimazole lotion (Triben), teneligliptin + metformin
HCl ER tablet, teneligliptin + metformin HCl SR tablet (Dynaglipt-M),
paracetamol+caffeine+ phenylephrine+diphenhydramine tablet (Kolq – C).
Retail
price is applicable only to the individual manufacturers/marketeers
i.e. who have applied for the same by submitting Form-I for price
fixation/revision as stipulated under DPCO, 2013 and subject to
fulfillment of all the applicable statutory requirements as laid down by
the government under relevant statutes/rules, including manufacturing
license permission from the Competent Authority i.e. the Central/State
Licensing Authority, as may be applicable, by the concerned
manufacturers/marketing companies.
The concerned manufacturers of
said formulations shall furnish quarterly return to the NPPA, in
respect of production/import and sale of product in Form-III of
Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case
intending to discontinue above said formulations, shall furnish
information to the NPPA, in respect of discontinuation of the production
and/or import of above said formulation in Form-IV of Schedule-II of
the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
In case the retail price of any of the
formulations is not complied with, as per instant price notification and
notes specified, then the concerned manufacturer/marketing company
shall be liable to deposit the overcharged amount along with the
interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
Consequent to the issue of
retail price of the formulations as specified in this notification, the
price order(s) if any, issued for concerned manufacturer/marketeer prior
to said date of notification, stand(s) superseded, the NPPA said in the
notification.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|